Incyte Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ICY.F | 9969.HK | IOVA | GMAB | 1530.HK | 1877.HK | |
|---|---|---|---|---|---|---|
| Market cap | 20.99B | 20.76B | 6.47B | 24.53B | 33.76B | 16.97B |
| P/E (TTM) | 15.4 | 19.6 | — | 31.4 | 3.7 | — |
| Forward P/E | 23.5 | 55.5 | -73.0 | 26.3 | 10.0 | 82.7 |
| Price/book | 3.7 | 2.3 | 8.8 | 4.0 | 1.1 | 2.4 |
| Dividend yield | — | — | — | — | 1.75% | — |
| 1-year change | +34.23% | −8.32% | +567.58% | +32.47% | −47.31% | −32.07% |
| Today | +2.12% | −6.52% | −2.29% | +0.83% | −4.62% | −3.84% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ICY.F news ›Barclays Keeps Their Buy Rating on Incyte (INCY)
Barclays analyst Etzer Darout maintained a Buy rating on Incyte today and set a price target of $139.00. Darout covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Summit Therapeutics, and AnaptysBio.…
Canaccord Genuity Sticks to Their Buy Rating for Incyte (INCY)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Incyte, with a price target of $152.00. According to TipRanks, Newman is an analyst with an average return of -2.8% and a 39.11% success rate. Newman…
Rheumatoid Arthritis Pipeline 2026: Key Companies, Clinical Trial Progress, and Mechanism of Action Insights by DelveInsight | Abbvie, Eli Lilly, Incyte, Taiho Pharma, Rise Therapeutics, Cyxone
Albany New York October 21 2026 As per DelveInsight s assessment globally Rheumatoid Arthritis pipeline constitutes 75 key companies continuously working towards developing 80 Rheumatoid Arthritis treatment therapies analysis of Clinical…
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)
Posted by Mitch Edgeman on Oct 20th, 2026 Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Incyte (NASDAQ:INCY – Get Free Report) are both large-cap healthcare companies, but which is the better stock? We will contrast the two…
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Four rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody Both investigational therapies are being evaluated in ongoing Phase 3 programs WILMINGTON,…
Incyte officer Pablo J. Cagnoni sells 2,642 shares
An Incyte (INCY) officer exercises options and sells 2,642 shares at $112.71. Stock Titan Incyte officer Pablo J. Cagnoni sells 2,642 shares For the 839-share option lot, options become exercisable in 37 installments beginning January 17,…
7,443 Incyte Corporation $INCY Shares Bought by Farther Finance Advisors LLC
Farther Finance Advisors LLC grew its holdings in Incyte Corporation (NASDAQ:INCY – Free Report) by 410.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,256 shares of the…
Incyte officer proposes $298K sale of common shares
The shares came from a cash stock option exercise on October 15, 2026, also the approximate sale date. The notice lists five prior sales. Incyte officer proposes $298K sale of common shares The notice lists five earlier sales, including…
Spotlight On: Niktimvo's IPF miss adds to mounting pressure on Incyte
FirstWord Pharma
Incyte Corporation $INCY Stock Sold by Forvis Mazars Wealth Advisors LLC
Posted by Tristan Rich on Oct 13th, 2026 Get Our Latest Stock Report on INCY Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
themarketsdaily.com6
-
theglobeandmail.com4
-
kalkinemedia.com3
-
stocktitan.net3
-
tradingview.com2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 28 articles, not a forecast.